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Abstract 
Pairwise meta-analysis is an established statistical tool for synthesizing evidence from multiple trials 
but it is informative only about the relative efficacy of two specific interventions. The usefulness of 
pairwise meta-analysis is thus limited in real-life medical practice, where many competing 
interventions may be available for a certain condition and studies informing some of the pairwise 
comparisons may be lacking. This commonly encountered scenario has led to the development of 
network meta-analysis (NMA). In the last decade several applications, methodological developments 
and empirical studies in NMA have been published and the area is thriving as its relevance to public 
health is increasingly recognized. This article presents a review of the relevant literature on NMA 
methodology aiming to pinpoint the developments that have appeared in the field. 
Keywords: mixed-treatment comparison; multiple treatment meta-analysis; indirect treatment 
comparison; comparing multiple interventions; 
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1 Introduction 
When developing a new treatment for a particular disease, a series of clinical trials are conducted 
where its efficacy is compared to a placebo and/or to a competing treatment that is already 
implemented in regular care. As a consequence, when reviewing estimates of treatment efficacy 
researchers often encounter clinical trials comparing different subsets of all the available treatments for 
the disease, forming a ‘network’ of evidence (Salanti et al., 2008a). In this situation a standard meta-
analysis restricted to head-to-head comparisons cannot give a definite answer as to which treatment 
works best for a specific condition. Network meta-analysis can then be used to synthesize the totality of 
the available information and provide clinically relevant estimates to better support decision-making 
(Caldwell et al., 2005; Coleman et al., 2012; Higgins and Whitehead, 1996; Lu and Ades, 2004; 
Lumley, 2002).  
In the past few years NMA has become increasingly popular (Coleman et al., 2012; D’Ascenzo and 
Biondi-Zoccai, 2014; Donegan et al., 2010; Glenny et al., 2005; Nikolakopoulou et al., 2014; Sobieraj 
et al., 2013) and several published articles have discussed its advantages and limitations (Cipriani et al., 
2012; Cooper et al., 2011; Cucherat and Izard, 2009; EUnetHTA – European network for Health 
Technology Assessment (last), 2013; Hoaglin et al., 2011; Ioannidis, 2009; Jansen et al., 2011a, 2008; 
Malone, 2007; Mills et al., 2013b, 2011a; Naci and Fleurence, 2011; Salanti, 2012; Sutton et al., 2008, 
2009; Wells et al., 2009; Welton et al., 2012), which have also been explored in empirical assessments 
(Jonas et al., 2013; Madan et al., 2011; O’Regan et al., 2009; Song et al., 2008, 2003) and simulation 
studies (Glenny et al., 2005; Jonas et al., 2013; Song et al., 2012). In particular, NMA allows an 
increase in the precision of estimates of relative effects (as compared to estimates based on direct 
evidence alone) and it can be used to compare interventions that have never been compared directly, 
head-to-head. This is especially valuable when active agents are only compared to placebo or standard 
care for regulatory purposes but not to each other (Falissard et al., 2009). In addition, NMA can support 
(policy-related) decision-making by explicitly providing a ranking of all competing interventions 
(Salanti et al., 2011) and to reduce the uncertainty in input parameters for subsequent formal cost-
effectiveness models (Thorlund et al., 2014).  
Despite the aforementioned advantages, the implementation of NMA may be hindered due to 
several reasons. First, the methodology of NMA rests on the assumption that different sources of 
evidence (direct and indirect evidence for the same treatment comparison) are in agreement. This 
assumption is often viewed as an important limitation of the method because it may be difficult to 
justify in practice. Moreover, the field of NMA is swiftly evolving; during the last few years there has 
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been an abundance of published articles presenting alternative approaches to deal with issues related to 
NMA. Hence, an updated review of the methodology is deemed timely to ensure that interested 
researchers use state-of-the-art methods for practical applications and also when conducting further 
methodological research. The present article aims to give a comprehensive account of the currently 
available methods for NMA, discuss in depth conceptual and statistical ways of evaluating the 
underlying assumptions of the model while providing guidance for researchers that set out to perform 
an NMA.  
This review is part of work undertaken within the auspices of GetReal: Incorporating real-life data 
into drug development, a project funded by the Innovative Medicines Initiative (IMI) – a European 
public-private initiative aiming to speed up the development of better and safer medicines for patients. 
The aim of the GetReal project is to explore how drug development can become more efficient by 
better incorporating evidence of relative effectiveness in the process, and to propose ways for enriching 
the decision-making by regulatory authorities and HTA. This article is part of a series of three literature 
reviews (Debray et al., 2015; Panayidou et al., 2015).   
2 Literature review methods and results  
Search strategy 
For the purposes of this review we searched for published articles that presented new methodology 
for NMA or articles that evaluated existing methods. We based our search on a previous review of the 
literature in NMA performed by the ‘Comparing Multiple Interventions Methods Group’ of the 
Cochrane Collaboration, which resulted in a publicly available database 
(www.zotero.org/groups/network_meta-analysis_methods/items/). This database has been shared with 
experts in the field to identify missing relevant articles. We also used the results from a recent literature 
review performed by Donegan et al. (Donegan et al., 2013b). In addition, we searched the MEDLINE 
database and also hand-searched key journals. Details on the search strategy we employed can be found 
in Appendix 2. 
Inclusion criteria 
We included articles that contributed to the methodology of network meta-analysis by introducing 
new methods and models; articles that reviewed the existing methodology and articles that provided 
recommendations or gave guidance on how to perform an NMA. We also included papers that 
discussed the conceptual issues and the assumptions behind NMA and articles that provided some sort 
of empirical assessment for the conduct of network meta-analyses in general.  
Exclusion Criteria 
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We excluded publications for which one of the following criteria was met: 
• full text of the publication was not available 
• published in a language other than English 
• conference posters 
• applications of NMA without a methodological focus 
Results 
A total of 179 articles were included in our database. The identified articles were organized 
according to their context and are discussed in the relevant sections of this review. The included papers 
were classified using a number of tags. Each article was assigned one or more tags according to the 
type of research presented, one or more tags according to the methodological topics addressed and one 
or more tags according to the software it used to implement the methods it presented. An online 
database of all included articles tagged by topic can be found at https://www.zotero.org/groups/wp4_-
_network_meta-analysis/items. More details on the results and the categorization we used are discussed 
in Appendix 2.  
In the next sections we present a review of the methods for NMA as identified in our literature 
search. In Section 3 we present key concepts and the basic methodology for NMA. We present the 
underlying assumptions of the model in Section 3.1 and we discuss popular approaches for fitting 
NMA in Section 3.2. We present methods for detecting inconsistency in the network in Section 4. In 
Section 5 we give a list of the software options available for fitting NMA models and evaluating 
inconsistency. In Section 6 we present special issues of the NMA methodology. We discuss the use of 
different effect sizes (Section 6.1) and how to model time-to-event data (Section 6.2). In Section 6.3 we 
give methods to allow the inclusion of covariates in the analysis. In Section 6.4 we explore ways for 
adjusting for possible sources of bias and in Section 6.5 we discuss the reporting of the results of an 
NMA. We review available methods for analyzing multiple outcomes and repeated measures in Section 
6.6 and we discuss the definition of nodes in the network of treatments in Section 6.7. In Section 6.8 
we review the use of Individual Participant Data (IPD) in an NMA and in Section 6.9 we discuss the 
use of data from non-randomized studies in the analysis. Finally in Section 6.10 we discuss how NMA 
can inform the planning of future studies. 
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3 Basic methodology in NMA 
3.1 Conceptual issues and underlying assumptions 
The key feature of NMA is that it allows the synthesis of direct and indirect estimates for the 
relative effects of many competing treatments for the same health condition. Two treatments A and B 
may have been directly compared in head-to-head studies (in ‘AB’ studies). An indirect estimate may 
also be obtained from studies comparing these two treatments with a common comparator treatment C, 
i.e. AC and BC studies (Bucher et al., 1997). If both direct and indirect estimates are available, they can 
be combined in order to estimate a mixed treatment effect, as shown in the left panel of Figure 1. In 
practice, for most health conditions there is a plethora of interventions being compared across various 
randomized trials, forming a network of evidence. For a given treatment comparison within such a 
network there may be direct and many different indirect estimates, obtained via many different 
comparators as shown in the example of the right panel of Figure 1. Using NMA one can synthesize all 
these different pieces of information to produce an internally consistent overall estimate of all 
treatments’ relative effects.   
FIGURE 1 HERE 
Despite the benefits of NMA discussed in the Introduction, there is still controversy among 
researchers about the validity of using indirect treatment comparisons (indirect evidence) for decision 
making. The use of such evidence is particularly challenged when direct treatment comparisons (direct 
evidence) are also available (Edwards et al., 2009; Gartlehner and Moore, 2008; Ioannidis, 2006). One 
focal point of criticism is the nature of evidence NMA provides. Even though patients within an RCT 
are randomized to each of the treatments being compared, the treatments are not randomized across the 
included trials. Therefore, indirect comparisons are non-randomized comparisons and in fact provide 
observational, rather than randomized, evidence. As a consequence indirect treatment comparisons may 
be more subject to biased treatment effect estimates, due, for example, to confounding (e.g. when 
randomized AB and AC studies are systematically different than BC (Caldwell et al., 2005)) and 
selection bias (e.g. when the choice of comparator in a study is dependent on the relative treatment 
effect (Salanti et al., 2008b)). Such considerations are also closely related to the underlying 
assumptions of NMA; in what follows we discuss these assumptions in detail. 
3.1.1 Transitivity 
The objective of an NMA is to enhance the decision-making process regarding the choice among 
alternative treatments for a certain disorder and a target population. Thus, the estimands one aims to 
estimate in an NMA are the average relative treatment effect sizes between the competing treatments, 
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as they are expected to exist in the targeted population. The estimates produced by an NMA model for 
these parameters will be unbiased and consistent provided that the studies included in the dataset yield 
unbiased estimates and form a representative sample of the population of interest, and when the 
assumptions employed by the NMA model are valid. NMA adopts the same set of assumptions as a 
pairwise meta-analysis (Dias et al., 2010b) but it also employs an additional assumption which can be 
hard to assess (Song et al., 2009) termed transitivity (Baker and Kramer, 2002) (also called similarity 
(Donegan et al., 2010; Song et al., 2003) or exchangeability (Dias et al., 2013d)). Transitivity implies 
that information for the comparison between treatment A and B can be obtained via another treatment 
C, using the comparisons A vs. C and B vs. C. This assumption cannot be tested statistically, but its 
validity can be evaluated in a conceptual and epidemiological manner (Salanti, 2012). 
The transitivity assumption implies that we can combine the direct evidence from AC and BC 
studies to learn (indirectly) about the comparison AB. This, however, will be questionable if there are 
important differences in the distribution of the effect modifiers (variables or characteristics which 
modify the observed relative effects, e.g. mean age of the participants, treatment dosage etc.) across the 
AC and BC trials which inform the indirect comparison (Baker and Kramer, 2002; Jansen and Naci, 
2013). An effect modifier might differ across studies of the same comparison (e.g. mean participant age 
might be different across the AC trials) but if it has a similar distribution across comparisons (AC and 
BC) the transitivity assumption may still be valid (Salanti, 2012). Consequently, the plausibility of the 
transitivity assumption can be evaluated by putting the collection of studies under scrutiny for 
important differences in the distribution of effect modifiers. If the studies are deemed to be similar then 
the transitivity assumption might be realistic, provided that there are no unknown modifiers of the 
relative treatment effect (Donegan et al., 2013b). Obviously, such an evaluation of transitivity may be 
impossible when the effect modifiers are not reported or when there are few studies per treatment 
comparison (Cipriani et al., 2013). If important differences are identified and there are enough data 
available, a network meta-regression can be used to improve the transitivity of the network (see also 
Section 6.3). 
The transitivity assumption also implies that the common comparator treatment C must be similar in 
the AC and in the BC studies in terms of dose, modes of administration, duration etc. In an NMA of 
studies comparing fluoride treatments for the prevention of dental carries, the definition of placebo was 
different between studies of fluoride toothpaste and studies of fluoride rinse (Salanti et al., 2009), 
casting doubt about the plausibility of the transitivity assumption and thereby challenging the reliability 
of NMA results. In another example, Julious and Wang (Julious and Wang, 2008) discussed how the 
use of placebo as an intermediate comparator might bias the results of indirect comparisons due to 
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changes in the placebo response of the population over the years; for example, when studies comparing 
treatment A to placebo are older than studies comparing B to placebo the indirect estimate for A vs. B 
via placebo may be biased.  
Other ways of formulating the transitivity assumption is to assume that regardless of the treatments 
being compared in each study the true relative effect of A vs. B is the same in a fixed effects model or 
exchangeable across studies in a random effects model (Dias et al., 2013d; Lu and Ades, 2009), that the 
‘missing’ treatments in each trial are missing at random (Lu and Ades, 2006) or, equivalently, that the 
choice of treatment comparisons in the trials is not associated either directly or indirectly with the 
relative effectiveness of the interventions (Salanti, 2012). Finally, an alternative way of postulating this 
assumption is to state that the included patients could in principle be randomized to any of the 
treatments included in the network (Salanti, 2012). 
3.1.2 Consistency 
The statistical manifestation of transitivity is called consistency (Cipriani et al., 2013). Checking the 
network for consistency constitutes an additional method of inferring indirectly about the plausibility of 
the transitivity assumption. Consistency refers to the statistical agreement between the observed direct 
and the (possibly many) indirect sources of evidence. A simple network may only include three 
treatments A, B and C. The transitivity assumption then implies that 𝜇𝜇𝐴𝐴𝐴𝐴 = 𝜇𝜇𝐴𝐴𝐴𝐴 − 𝜇𝜇𝐴𝐴𝐴𝐴 (also termed 
consistency equation), where 𝜇𝜇𝐴𝐴𝐴𝐴 denotes the true relative effect of treatment B over C; likewise for 
𝜇𝜇𝐴𝐴𝐴𝐴 , 𝜇𝜇𝐴𝐴𝐴𝐴 . When this equation does not hold for the (direct) estimates, the network is said to be 
inconsistent (Lu and Ades, 2006) or incoherent (Lumley, 2002). If this is the case, results from an 
NMA will be more difficult to interpret and become less reliable. In a following section we review 
various statistical methods and models that have been suggested for identifying inconsistency and thus 
assessing the transitivity assumption in NMA.  
Statistical inconsistency can be thought of as another form of heterogeneity: heterogeneity results 
from the variation of effect modifiers within a treatment comparison, while inconsistency results from 
the variation of effect modifiers across treatment comparisons (Jansen and Naci, 2013). Researchers 
should keep in mind, though, that the consistency of a network can only be assessed statistically when 
there is both direct and indirect evidence for one or more treatment comparisons. This situation only 
occurs when there are closed loops in the network (i.e. when three or more interventions are connected 
by a polygon, the edges of which represent head-to-head comparisons between the corresponding 
treatments). When there are no closed loops present in the network, a statistical assessment of 
inconsistency will not be possible. In these situations there cannot be inconsistency by definition. This, 
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however, does not imply that the transitivity assumption will necessarily hold. It should also be noted 
that the absence of statistical inconsistency (in the presence of loops) does not provide proof for the 
validity of the transitivity assumption, which, as discussed in the previous section is essentially an 
untestable assumption. Thus, next to statistical tests for inconsistency, a conceptual/theoretical 
assessment of the transitivity assumption should always take place before an NMA is conducted 
(Cipriani et al., 2013) and the studies included in an NMA should always be scanned for important 
differences in terms of patients, interventions, outcomes, study design, methodological characteristics 
and reporting biases (Bucher et al., 1997; Caldwell et al., 2005; Coleman et al., 2012; Coory and Jordan, 
2010; Cucherat and Izard, 2009; Dewilde and Hawkins, 2012; Donegan et al., 2013b; Glenny et al., 
2005; Griffin et al., 2006; Hoaglin et al., 2011; Jansen et al., 2008; Madan et al., 2011; van Valkenhoef 
et al., 2012c; Wells et al., 2009; Xiong et al., 2013).  
3.2 Statistical methods for NMA 
A simple network may include three treatments of interest, A, B and C. An estimate of the indirect   
treatment effect of A vs. B can then be obtained by utilizing the direct observations A vs. C and B vs. C 
as  ?̂?𝜇𝐴𝐴𝐴𝐴𝐼𝐼𝐼𝐼𝐼𝐼 = ?̂?𝜇𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷 − ?̂?𝜇𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷 (Bucher et al., 1997). This result is sometimes also referred to as “adjusted 
indirect comparison”. The variance of the indirect estimate is the sum of the variances of the two direct 
ones. When direct evidence is also available for the A vs. B comparison it can be combined with the 
indirect estimate using the inverse variance method to produce a mixed estimate. Note that this 
approach for obtaining indirect estimates is only valid for ‘triangular networks’, where three treatments 
have been compared in a number of two-arm trials (and it can be readily extended for ‘polygonal 
networks’ with no diagonals); it can also be used for ‘star-shaped’ networks, where all treatments are 
compared to a common comparator (e.g. placebo) but not to each other. For complex networks, e.g. 
like the one depicted in the right panel of Figure 1, there will be multiple sources of indirect 
information and thus more advanced models need to be used. 
Popular implementations of NMA models adopt meta-regression (Section 3.2.1), hierarchical 
modelling (Section 3.2.2) or a multivariate meta-analysis approach (Section 3.2.3). A common feature 
of all of these approaches is that the use of the consistency equations minimizes the number of 
parameters that need to be estimated. The minimum set of parameters needed to model the relative 
treatment effects is usually termed as the set of “basic parameters” or “basic contrasts”; these 
parameters are (assuming that the network is connected) in number equal to the number of treatments 
minus one and can be used to generate estimates for all possible treatment comparisons via the 
consistency equations (i.e. 𝜇𝜇𝛸𝛸𝛸𝛸 = 𝜇𝜇𝛸𝛸𝛸𝛸 − 𝜇𝜇𝛸𝛸𝛸𝛸 for treatments 𝑋𝑋, 𝑌𝑌 and 𝑍𝑍). The basic parameters can be 
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chosen arbitrarily as long as they form a “spanning tree” of the evidence, i.e. they form a connected 
subgraph of the network containing all vertices but no cycles (Lu and Ades, 2006); if this condition is 
satisfied the actual choice of basic parameters does not affect the NMA results. These parameters are 
commonly taken to be the relative effects of each treatment versus a reference (e.g. the placebo, if 
present in the network). For example, for a network of four treatments A, B, C and D three basic 
parameters are needed. These can be chosen to correspond to the relative treatment effects of all other 
treatments versus A, i.e. AB, AC and AD. All other treatment effects can be generated from these 3 
parameters, e.g. the relative treatment effect for BD can be estimated using the AB and AD parameters. 
Choosing instead BA, BC and BD as the basic parameters would have no impact on the NMA results.  
In what follows we describe some of the most common approaches for fitting an NMA model. 
These approaches should be considered equivalent; the choice between them should be primarily 
dictated by the availability of software packages for implementing them and by the technical expertise 
of the researchers. Different methods may give slightly different estimates, e.g. fitting an NMA in a 
Bayesian framework as a hierarchical model may lead to slightly different results than fitting it in a 
frequentist setting using multivariate meta-analysis techniques. These differences, however, should not 
be seen as a limitation of NMA models in general; they are due to the different approaches employed 
for making statistical inferences, in a similar way as it applies to a pairwise meta-analysis. We discuss 
the currently available software options for fitting all the models and implementing all the methods in 
Section 5. 
3.2.1 NMA as a meta-regression 
In the meta-regression approach, first proposed by Lumley (Lumley, 2002) the various treatment 
comparisons are treated as covariates in a meta-regression model (Salanti et al., 2008a). The usual 
ΝΜΑ meta-regression model can be summarized in the following equation: 𝒚𝒚 = 𝜲𝜲𝝁𝝁 + 𝜺𝜺 + 𝜹𝜹, with 𝒚𝒚 
being the vector of observed relative treatment effects, 𝝁𝝁 the vector of basic parameters, 𝜺𝜺 the vector of 
random errors, and 𝜹𝜹  the vector of random effects. Note that for a study 𝑖𝑖 comparing 𝑇𝑇𝐷𝐷  different 
treatments, only 𝑇𝑇𝐷𝐷 − 1 observations on treatment comparisons need to enter the model. For a parallel 
randomized three-arm ABC trial, for example, we only need to include two of the three comparisons, 
e.g. AB and AC; the BC comparison is just a linear function of the other two. This means that 𝒚𝒚, 𝜺𝜺 and 
𝜹𝜹  have a length equal to ∑(𝑇𝑇𝐷𝐷 − 1) . Random errors are assumed to follow a multivariate normal 
distribution, 𝜺𝜺~𝛮𝛮(0,𝑺𝑺), with 𝑺𝑺 being the (block-diagonal), within-study variance covariance matrix. A 
study 𝑖𝑖 with 𝑇𝑇𝐷𝐷 treatments arms will contribute a (𝑇𝑇𝐷𝐷 − 1) × (𝑇𝑇𝐷𝐷 − 1) matrix to 𝑺𝑺; a two-arm AB study, 
for example, will only contribute to 𝑺𝑺 the variance of the relative treatment effect of A vs. B. A three-
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arm trial ABC will contribute to 𝑺𝑺 a 2 × 2 matrix with the variances and the covariance of the 2 
relative treatment effects chosen to be included in 𝒚𝒚, e.g. AB and AC. Similarly, 𝜹𝜹~𝛮𝛮(0,𝜟𝜟) for the 
random effects, with 𝜟𝜟  being the heterogeneity variance-covariance matrix. Matrix 𝑿𝑿 , the design 
matrix, has as elements 1, –1 and 0 and describes the structure of the network, providing information 
on which comparison is being performed in each study (Salanti et al., 2008a). If for example the 
network is built by an AB study (study 1), an AC study (study 2) and a BC study (study 3), the model 
would be written as: 
�
𝑦𝑦1𝐴𝐴𝐴𝐴
𝑦𝑦2𝐴𝐴𝐴𝐴
𝑦𝑦3𝐴𝐴𝐴𝐴
� = � 1 00 1
−1 1��𝜇𝜇𝛢𝛢𝛢𝛢𝜇𝜇𝐴𝐴𝐴𝐴� + �𝜀𝜀1𝐴𝐴𝐴𝐴𝜀𝜀2𝐴𝐴𝐴𝐴𝜀𝜀3𝐴𝐴𝐴𝐴� + �𝛿𝛿1𝐴𝐴𝐴𝐴𝛿𝛿2𝐴𝐴𝐴𝐴𝛿𝛿3𝐴𝐴𝐴𝐴�. 
The basic parameters can be estimated as 𝝁𝝁� = (𝜲𝜲𝜯𝜯𝑾𝑾𝑿𝑿)−1𝑿𝑿𝑻𝑻𝑾𝑾𝒚𝒚 , with variance 𝑣𝑣𝑣𝑣𝑣𝑣(𝝁𝝁�) =(𝜲𝜲𝜯𝜯𝑾𝑾𝑿𝑿)−1 , where 𝑾𝑾 is the weight matrix, 𝑾𝑾 = (𝑺𝑺 + 𝜟𝜟)−1 . The within-study variance-covariance 
matrix 𝑺𝑺 can be estimated from the observed data (Franchini et al., 2012; Higgins and Whitehead, 
1996), while for the between-study variance-covariance matrix  𝜟𝜟  one can use various ways of 
estimation including likelihood methods or the methods of moments (Berkey et al., 1998; Jackson et al., 
2010; van Houwelingen et al., 2002). Estimating 𝜟𝜟 may be difficult especially when the data are sparse 
or in the presence of multi-arm studies. For this reason, it is common to introduce additional 
assumptions to reduce the number of parameters in 𝜟𝜟 and simplify the estimation. The most common 
approach is to assume equal heterogeneity variances across comparisons, i.e. the between-study 
heterogeneity of the relative treatment effects is the same for all treatment comparisons (Higgins and 
Whitehead, 1996; Lumley, 2002). This assumption is, however, quite strong and may often be 
unrealistic. Lu & Ades (Lu and Ades, 2009) discussed how the consistency equations impose 
restrictions on the heterogeneity of each comparison, based on the (different) heterogeneity variances 
of each of the basic parameters. Thorlund et al. (Thorlund et al., 2013) presented models for 
exchangeable heterogeneity variances and also discussed the use of informative prior distributions in 
the context of a Bayesian analysis.  
In a different approach, Lu et al. proposed a two-stage method for performing an NMA as a meta-
regression (Lu et al., 2011). At the first stage a meta-analysis is performed in each group of trials 
comparing the same treatments, e.g. all two-arm trials that compare A vs. B, all three-arm trials that 
compare A vs. B vs. C, etc. This provides the direct estimates on treatment comparisons. At the second 
stage of the meta-analysis, a weighted linear regression is performed with the direct estimates as 
dependent variables. This two-stage method can be used to investigate how the first-stage (direct) 
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evidence influences the network estimates and may therefore help to assess the consistency of the 
network (see Section 4).  
3.2.2 NMA as a hierarchical model 
Hierarchical NMA models (Lu and Ades, 2004; Salanti et al., 2008a) appear to be implemented 
most often (Coleman et al., 2012; Nikolakopoulou et al., 2014). An important advantage of this 
approach is that if arm-level data are available, their exact likelihood can be used (Dias et al., 2013a).  
The likelihood of the arm-level data is defined in terms of a set of unknown parameters 𝛾𝛾 and a link 
function, 𝑔𝑔(𝛾𝛾) which is used to map these parameters in the (−∞,∞) range. For a study 𝑖𝑖 comparing 
treatments A and B we set: 
𝑔𝑔(𝛾𝛾𝐷𝐷𝐴𝐴) = 𝑢𝑢𝐷𝐷, 
𝑔𝑔(𝛾𝛾𝐷𝐷𝐴𝐴) = 𝑢𝑢𝐷𝐷 + 𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴. 
For the case of binary data, for example, we can choose 𝑔𝑔  to be the 𝑙𝑙𝑙𝑙𝑔𝑔𝑖𝑖𝑙𝑙  function and 𝛾𝛾  the 
probability of observing an event. We set:  
𝑙𝑙𝑙𝑙𝑔𝑔𝑖𝑖𝑙𝑙(𝑝𝑝𝐷𝐷𝐴𝐴) = 𝑢𝑢𝐷𝐷, 
𝑙𝑙𝑙𝑙𝑔𝑔𝑖𝑖𝑙𝑙(𝑝𝑝𝐷𝐷𝐴𝐴) = 𝑢𝑢𝐷𝐷 + 𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴. 
Here 𝑢𝑢 represents the log-odds of the outcome for treatment A and 𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴 the log-odds ratio of A versus 
B; the event probabilities for each arm parameterize the binomial likelihood, 𝑣𝑣𝐷𝐷𝑖𝑖~𝐵𝐵𝑖𝑖𝐵𝐵(𝑝𝑝𝐷𝐷𝑖𝑖,𝐵𝐵𝐷𝐷𝑖𝑖), with 
𝑣𝑣𝐷𝐷𝑖𝑖 denoting the events and 𝐵𝐵𝐷𝐷𝑖𝑖 the total number of randomized patients in each treatment arm (𝑇𝑇 =
𝐴𝐴,𝐵𝐵).  We then allow 𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴~𝑁𝑁(𝜇𝜇𝐴𝐴𝐴𝐴, 𝜏𝜏𝐴𝐴𝐴𝐴2 )  for a random-effects meta-analysis. If two non-reference 
treatments are compared in a study, e.g. treatments B and C, we utilize the consistency equations by 
setting 𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴~𝑁𝑁(𝜇𝜇𝐴𝐴𝐴𝐴 − 𝜇𝜇𝛢𝛢𝛢𝛢 , 𝜏𝜏𝐴𝐴𝐴𝐴2 ).  In the presence of multi-arm studies multivariate normal 
distributions should be used instead, where the within- and between-study variances are replaced by the 
corresponding variance-covariance matrices 𝑺𝑺𝒊𝒊 and 𝜟𝜟𝒊𝒊. Details on how to model other types of data can 
be found in (Dias et al., 2013a). Note that the issues discussed in the previous section regarding the 
estimation of the between-trial heterogeneity hold for the hierarchical models as well. 
NMA can be fitted as a hierarchical model also if only contrast-level data are available from the 
studies (i.e. when the reported data is on the relative treatment effects of the treatments being 
compared, but not on the specific arms). For a two-arm study 𝑖𝑖 comparing A (reference treatment) and 
B the model is written as 𝑦𝑦 𝐷𝐷𝐴𝐴𝐴𝐴~𝑁𝑁(𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴, 𝑠𝑠𝐷𝐷2). Note here that the normality assumption can be justified 
even if the underlying patient-level distributions are skewed, due to the central limit theorem (Dias et 
al., 2013a).  
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Hierarchical models can also be fitted when a combination of arm-level and contrast-level data is 
available, using the exact likelihood for the arm-level data and the normal approximation for the 
contrast-level data in a so-called shared parameter model (Dias et al., 2013a).  
3.2.3 NMA as a multivariate meta-analysis model 
White et al. (White et al., 2012) suggested a method for performing NMA as a multivariate meta-
analysis by treating the basic comparisons as different outcomes and by employing standard multiple-
outcome meta-analytical techniques (Mavridis and Salanti, 2013). For this model to work all studies 
need to report on the reference treatment; if this is not the case for some studies, a data-augmentation 
technique is required to impute a minimally informative reference treatment arm. The model is written 
as 𝒚𝒚 =  𝜲𝜲∗𝝁𝝁 + 𝜺𝜺 + 𝜹𝜹, with 𝜲𝜲∗  being a matrix with all elements either 0 or 1, depending on which 
‘outcomes’ are reported in each study.  
Assume for example that treatments A, B and C are compared in a number of studies, and also 
assume that treatment A is taken to be the reference treatment. In this approach 𝝁𝝁 will be a 2 × 1 vector 
of the basic parameters, AB and AC. A study comparing A vs. B will contribute an element 1 in the 
first column of 𝜲𝜲∗ and 0 in the second, since in this study only the first ‘outcome’ is reported. An A vs. 
C study will report the second outcome only, thus the relevant elements in 𝜲𝜲∗  will be 0 and 1 
respectively. For a B vs. C study, however, an A arm must be imputed; this study becomes three-arm, 
and reports on both ‘outcomes’. The model for these three studies is as follows: 
�
𝑦𝑦1𝐴𝐴𝐴𝐴
𝑦𝑦2𝐴𝐴𝐴𝐴
𝑦𝑦3𝐴𝐴𝐴𝐴
𝑦𝑦3𝐴𝐴𝐴𝐴
� = �1 00 11 00 1��𝜇𝜇𝛢𝛢𝛢𝛢𝜇𝜇𝐴𝐴𝐴𝐴� + �
𝜀𝜀1𝐴𝐴𝐴𝐴
𝜀𝜀2𝐴𝐴𝐴𝐴
𝜀𝜀3𝐴𝐴𝐴𝐴
𝜀𝜀3𝐴𝐴𝐴𝐴
� + �𝛿𝛿1𝐴𝐴𝐴𝐴𝛿𝛿2𝐴𝐴𝐴𝐴
𝛿𝛿3𝐴𝐴𝐴𝐴
𝛿𝛿3𝐴𝐴𝐴𝐴
� 
Note that the two random errors and also the two random effects that were included for the third 
study will be correlated. Also note that in this approach the vector of observations, 𝒚𝒚 has been modified 
to account for the imputed arms. Standard methods for multiple-outcome meta-analysis can now be 
used to fit the model. 
  Alternative models for performing an NMA have also been recently proposed in the literature. 
Rücker (Rücker, 2012) described the analogy between network meta-analysis and electrical networks 
and applied graph-theoretical methods to perform a fixed-effects NMA. This method was extended to 
also accommodate for random-effects and was shown to be equivalent to the meta-regression method 
described in Section 3.2.1 (Rücker and Schwarzer, 2014). Also, Yang et al. introduced a confidence 
distribution approach for performing an NMA (Yang et al., 2014). In this approach, instead of 
combining point estimates from each study, the authors combine confidence distributions.    
Published in final edited form as: Res Synth Methods. 2016 Sep;7(3):236-63. doi: 10.1002/jrsm.1195 
13 
 
For more in-depth reviews of the methodology that include the statistical details of the models we 
presented we refer the reader to (Cucherat and Izard, 2009; Greco et al., 2013; Ohlssen et al., 2013). 
4 Statistical methods for evaluating inconsistency in NMA 
As we have previously discussed (Section 3.1), transitivity is a central assumption of NMA. A 
statistical assessment of the plausibility of this assumption can be made by checking whether the 
various sources of evidence fit together in a coherent way. This assessment is vital for ensuring that the 
NMA results are valid and interpretable for clinical decision making (Donegan et al., 2012), but may be 
difficult to do in practice, especially in the case of complex networks or when multi-arm studies are 
included in the network. 
Statistical consistency can be assessed only in closed loops of evidence, and there are two general 
approaches to do this: either locally (by focusing on the inconsistency of a specific treatment 
comparison) or globally (by checking for inconsistency in the entire network of evidence). In what 
follows we discuss methods and models that have been proposed for both of these approaches. 
4.1 Local methods to detect inconsistency 
Loop-specific approach 
A straightforward approach for evaluating the presence of inconsistency in a network is to apply a 
loop-specific approach (Bucher et al., 1997); in this approach we examine each loop of the network in 
isolation from the rest of the network. For an ABC loop in the network, for example, we choose one of 
the comparisons (e.g. B vs. C) and compute the direct (?̂?𝜇𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷) and indirect estimates (?̂?𝜇𝐴𝐴𝐴𝐴𝐼𝐼𝐼𝐼𝐼𝐼). Their 
difference measures inconsistency and is usually termed inconsistency factor (Lu and Ades, 2006): 
𝑤𝑤�𝐴𝐴𝐴𝐴𝐴𝐴 = ?̂?𝜇𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷 − ?̂?𝜇𝐴𝐴𝐴𝐴𝐼𝐼𝐼𝐼𝐼𝐼, with variance 𝑣𝑣𝑣𝑣𝑣𝑣(𝑤𝑤�𝐴𝐴𝐴𝐴𝐴𝐴) = 𝑣𝑣𝑣𝑣𝑣𝑣(?̂?𝜇𝐴𝐴𝐴𝐴𝐼𝐼𝐼𝐼𝐼𝐼) + 𝑣𝑣𝑣𝑣𝑣𝑣(?̂?𝜇𝐴𝐴𝐴𝐴𝐷𝐷𝐷𝐷𝐷𝐷). A 95% confidence interval 
can be obtained as 𝑤𝑤�𝐴𝐴𝐴𝐴𝐴𝐴 ± 1.96�𝑣𝑣𝑣𝑣𝑣𝑣(𝑤𝑤�𝐴𝐴𝐴𝐴𝐴𝐴) and a Z-statistic for the null hypothesis of consistency, 
i.e. 𝑤𝑤�𝐴𝐴𝐴𝐴𝐴𝐴 = 0,  can be constructed as 𝑧𝑧𝐴𝐴𝐴𝐴𝐴𝐴 = 𝑤𝑤�𝐴𝐴𝐴𝐴𝐴𝐴/�𝑣𝑣𝑣𝑣𝑣𝑣(𝑤𝑤�𝐴𝐴𝐴𝐴𝐴𝐴) ; this can be compared with the 
standard normal distribution to obtain a p-value (Bucher et al., 1997). Inconsistency is a property of the 
loop, in the sense that choosing a different treatment comparison of the loop and repeating the 
computations would give the exact same results (Dias et al., 2013d; Lu and Ades, 2006); thus we 
denote the inconsistency factor with an ABC subscript.  
The loop-specific approach can be applied for each loop in a network to point out hotspots for 
inconsistency. The major advantage of this approach is that it is easy to implement, it suffers however 
from important limitations: when a treatment comparison is part of more than one loop this method 
does not compare direct evidence for this comparison to all available indirect information, but to 
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evidence from only one loop at a time; also in this case the tests for different loops sharing this 
comparison will not be independent. In addition, for networks with many loops there are multiple-
testing issues.  
Composite test 
 It is possible to extend the loop-specific approach by accounting for more than one indirect 
estimates for a treatment comparison using a ‘composite test’ for inconsistency (Caldwell et al., 2010; 
Dias et al., 2013d). Suppose that there are 𝐿𝐿 loops that provide independent indirect information for the 
A vs. B comparison; these can be combined with the direct information using the usual inverse 
variance method to obtain a pooled, overall estimate of the relative treatment effect of A vs. B. Under 
the null hypothesis that the 𝐿𝐿 + 1 different estimates are in agreement a test statistic following a chi-
squared distribution with 𝐿𝐿 degrees of freedom can be constructed to check for inconsistency. One 
should keep in mind, however, that the presence of multi-arm studies induces correlations among the 
estimates for the treatment effects which this method, as well as the loop-specific approach, fail to 
account for.  
Back-calculation 
Dias et al. also proposed two additional methods for locally checking inconsistency (Dias et al., 
2010b). The first method (“back-calculation”) can be applied when the only available data are the 
pooled summaries of the pairwise meta-analyses. In the first step, the data is used to obtain a network 
estimate for each pairwise comparison in the network. It is then assumed that this estimate is a 
weighted average of the direct and the indirect evidence, coming from the rest of the network. This 
allows a back-calculation of the indirect estimate and its variance, which in turn can be used to 
construct a Z-test for the difference of direct and indirect evidence. Note that this method is 
problematic for a random-effects meta-analysis, as the posterior distribution of the heterogeneity 
variance will in general be different between the NMA model and the model for the pairwise meta-
analysis.  
Node-splitting 
The second method proposed by Dias et al. (Dias et al., 2010b), the node-splitting approach, can be 
used when trial-level data are available. In this method the direct evidence for a specific treatment 
comparison is excluded from the rest of the network and is used to obtain a direct estimate. The 
remaining information in the network is used to obtain an indirect estimate for this comparison, after 
fitting an NMA model. The two estimates, direct and indirect, are then used to evaluate inconsistency 
with a Z-test. The main drawbacks of this approach (as well as the back-calculation approach) are that 
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they might be computationally intensive, especially for large networks with many treatment 
comparisons, and that they cannot properly handle multi-arm studies. 
4.2 Global methods to detect inconsistency 
The Lu and Ades model 
Lu and Ades introduced a model (Lu and Ades, 2006), in which the consistency equations are ‘bent’ 
by including extra terms, the inconsistency factors. For an ABC loop, for example, the consistency 
equation is written as 𝜇𝜇𝐴𝐴𝐴𝐴 = 𝜇𝜇𝐴𝐴𝐴𝐴 − 𝜇𝜇𝐴𝐴𝐴𝐴 + 𝑤𝑤𝐴𝐴𝐴𝐴𝐴𝐴, where the 𝑤𝑤 parameter measures the discrepancy of 
direct and indirect evidence. For networks comprising many loops a different inconsistency factor 
needs to be included in each loop. When the network only includes two-arm studies the number of 
independent inconsistency factors (the ‘inconsistency degrees of freedom’, 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼) is 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼 = 𝐼𝐼 − 𝑇𝑇 −1, with 𝐼𝐼 being the number of available pairwise comparisons in the data and 𝑇𝑇 the number of different 
treatments. The inconsistency factors can be assumed to follow a common distribution in order to 
increase the power in their estimation. A 𝜒𝜒2 test can be used to assess the inconsistency of the whole 
network, under the null assumption that all inconsistency factors are zero. In the presence of multi-arm 
studies, however, this model is problematic (van Valkenhoef et al., 2012b). Higgins et al. (Higgins et 
al., 2012) showed that different parameterizations of the model (choosing different reference treatment) 
may lead to different results. Thus, when multi-arm studies are present, the use of the Lu and Ades 
model should be avoided.  
The ‘Design-by-treatment’ inconsistency model 
Higgins et al. (Higgins et al., 2012) and White et al. (White et al., 2012) introduced an alternative 
inconsistency model, the ‘design-by-treatment’ interaction model, which encompasses both loop and 
design inconsistencies. The latter corresponds to the possible discrepancies in the treatment effects 
across designs, where ‘design’ refers to the treatments being compared in a study. For example, a study 
comparing treatments A and B is considered to be an AB design. The A vs. B estimate coming from 
such a study may be different than the A vs. B estimate coming from a three-arm study comparing 
treatments A, B and C (ABC design); this difference is referred to as design inconsistency. In the 
absence of multi-arm studies the Lu and Ades model is equivalent to the design-by-treatment model. 
Similarly to the Lu and Ades model, when multi-arm studies are present, the estimates of the 
inconsistency factors depend on the parameterization. Unlike the Lu and Ades model, however, the 
global statistic for inconsistency in the design-by-treatment interaction model is invariant under re-
parameterization. One limitation of the model is the increased complexity and the accompanying loss 
of power for the statistical test (Higgins et al., 2012). Another point of criticism for this approach is that 
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it adopts a somewhat arbitrary definition of design inconsistency, as it is mainly dictated by 
methodological rather than clinical considerations.  
 Jackson et al. (Jackson et al., 2014) presented an implementation of the design-by-treatment 
inconsistency model where they assumed random effects on the inconsistency factors. In the same 
paper the authors also derived 𝑅𝑅  and 𝐼𝐼2  statistics to quantify heterogeneity and inconsistency. In 
addition, an approach based on the notion of design-by-treatment inconsistency was also proposed by 
Piepho et al. (Piepho et al., 2012; Piepho, 2014; Piepho et al., 2015). 
Unrelated mean effects model 
An alternative method was introduced by Dias et al. (Dias et al., 2013d). In this model the 
consistency equations are completely removed and the network meta-analysis model is equivalent to a 
series of separate, independent meta-analyses for each pairwise contrast, sharing, however, a common 
heterogeneity variance (Caldwell et al., 2012). The fit of the model is then compared to the standard 
consistency NMA model using the posterior deviance and the deviance information criterion (DIC) 
(Spiegelhalter et al., 2002). In addition, estimating the contribution to posterior mean deviance for each 
data point can help identify possibly ‘problematic’ studies, i.e. studies not fitting well with the rest of 
the evidence. Each data point is expected to have a contribution of about 1 to the posterior mean 
deviance. A larger value will suggest a poor fit to the model, pointing out possibly inconsistent pieces 
of evidence. The use of leverage plots has been also suggested as a diagnostic tool for identifying 
studies with poor fit (Dias et al., 2010b). A limitation of the unrelated mean effects model is that in the 
presence of multi-arm studies a re-parameterization will affect the results of a random-effects meta-
analysis. 
𝑄𝑄 statistic for inconsistency 
A different approach for globally assessing inconsistency is by using the 𝑄𝑄 statistic for inconsistency 
(König et al., 2013; Krahn et al., 2013), which is analogous to the  𝑄𝑄 statistic for heterogeneity in 
simple meta-analysis. This approach is based on the two-stage method for fitting NMA (Lu et al., 
2011). On the first stage we perform a pairwise meta-analysis for the studies of each design available in 
the dataset, and obtain the direct relative treatment effect. From the AB studies, for example, we 
estimate ?̂?𝜇𝛢𝛢𝛢𝛢; this can be used to compute the 𝑄𝑄𝐴𝐴𝐴𝐴ℎ𝑒𝑒𝑒𝑒 statistic for heterogeneity as  𝑄𝑄𝐴𝐴𝐴𝐴ℎ𝑒𝑒𝑒𝑒 = ∑ 1𝑠𝑠𝑖𝑖2 (𝑦𝑦𝐷𝐷 −𝐷𝐷
?̂?𝜇𝛢𝛢𝛢𝛢)2, where 𝑖𝑖 runs through all AB studies. Similarly, on the second stage of the analysis we obtain 
network estimates for all pairwise comparisons; using these estimates and the direct estimates of the 
first stage, a 𝑄𝑄  statistic for the inconsistency of the whole network can be obtained and the null 
hypothesis of consistency in the network can be tested using a 𝜒𝜒2 distribution with 𝐼𝐼 − 𝑇𝑇 − 1 degrees 
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of freedom. This approach can be used in the presence of multi-arm studies. The authors also propose 
the use of a graphical tool, the net-heat plot, which provides a display of the flow of evidence in the 
network and can help identify potential hotspots for inconsistency. 
Also, Rücker and Schwarzer suggested a 𝑄𝑄  statistic for inconsistency using a graph-theoretical 
approach and showed that it is identical to the 𝑄𝑄 statistic described above (Rücker, 2012; Rücker and 
Schwarzer, 2014).  
Multidimensional scaling 
In a another graphical approach proposed by Chung and Lumley (Chung and Lumley, 2008) the 
multidimensional scaling method is used to infer about inconsistency in a network. For each pairwise 
comparison a usual inverse variance meta-analysis is performed; the magnitude of the relative 
treatment effects is considered to be a measure of the observed pairwise ‘dissimilarity’ of the 
treatments. The pairwise estimates are summarized in a dissimilarity matrix, to which a weighted 
multidimensional scaling is applied in order to obtain the ‘fitted dissimilarities’. Important differences 
between observed and fitted dissimilarities are an indicator of possible inconsistencies. Note that this 
method cannot properly handle multi-arm studies.  
4.3 Empirical studies and simulations on inconsistency 
Empirical studies show that the prevalence of inconsistency in published networks is non-trivial. 
Song et al. (Song et al., 2011) performed a meta-epidemiological study that included 112 published 
triangular networks, 16 of which were found to be statistically inconsistent. Veroniki et al. (Veroniki et 
al., 2013) evaluated inconsistency in 40 published networks including a total of 303 loops. They found 
that 2-9% of the loops were inconsistent, depending on the effect measure used and the assumptions for 
heterogeneity; also, approximately one eighth of the networks were found to be inconsistent using the 
design-by-treatment method. 
The various methods for assessing inconsistency have been rarely and poorly applied in published 
NMAs (Donegan et al., 2010). In a meta-epidemiological study by Nikolakopoulou et al. 
(Nikolakopoulou et al., 2014) it was found that in 24% of the published NMAs the authors did not use 
appropriate methods to evaluate inconsistency, while in 44% the authors did not report using any 
method at all. 
Song et al. (Song et al., 2012) performed simulations to evaluate the statistical properties of various 
methods for inferring about network inconsistency. They explored the use of the loop-specific approach, 
the node-splitting technique and the Lu & Ades model. They found that even though all methods are 
unbiased, they have little power in detecting inconsistency. It is also important to note that inferences 
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on inconsistency heavily depend on the extent of heterogeneity and the method used to evaluate it 
(Veroniki et al., 2013). Thus, analysts should keep in mind that a statistically non-significant estimate 
for inconsistency should not be interpreted as proof of consistency. In addition, even when statistically 
significant inconsistency is found, its magnitude should be interpreted in terms of clinical relevance; 
thus, a statistically-significant inconsistency in a certain loop might be clinically unimportant. 
4.4 Choosing between the methods for evaluating inconsistency  
If the network structure allows it, i.e. if there are closed loops in the network, a statistical assessment 
of inconsistency should always take place after fitting the NMA model. In the previous paragraphs we 
presented a variety of methods and models currently available for statistically checking the network for 
consistency and we discussed the advantages and limitations of each approach. In Table 1 we provide 
an overview of these approaches, including a brief summary of the limitations of each one. 
An assessment of inconsistency may start with the loop-specific approach which, despite its 
shortcomings, is the easiest one to implement and can pinpoint possibly problematic loops. Afterwards, 
if all studies in the network are two-armed, all presented strategies are valid choices for checking for 
inconsistencies. We generally recommend the application of both local and global methods to gain a 
better understanding of the source of possible discrepancies between direct and indirect evidence and 
the plausibility of the consistency assumption in the network as a whole. If the network includes multi-
arm studies only the design-by-treatment model and the 𝑄𝑄 statistic approach will lead to results that are 
independent of the parameterization of the model (i.e. the choice of the basic parameters). Researchers 
may still choose to implement some of the other methods as well, as exploratory analyses; they should 
bear in mind, however, that their results might not be robust.  
Approaches for evaluating inconsistency can also be selected based on the available technical 
expertise and/or software packages. In Table 2 we provide a summary of the currently available 
software solutions for implementing the various approaches. 
If statistically significant inconsistency is detected, researchers are advised to explore potential 
sources of it and try to explain it. Local methods for assessing inconsistency can indicate outlying 
studies, which should be checked for data extraction errors, important differences in the distribution of 
effect modifiers or other possible biases. In Section 6.3 we present various models for adding 
covariates and adjusting for suspected biases in the analysis. If sufficient studies are available, such 
models can be applied to explain and possibly eliminate inconsistencies, while, if inconsistency 
persists, researchers can consider splitting up the network (see discussion in Section 6.7). Finally, in the 
case of unexplained inconsistency, researchers may choose not to synthesize the evidence in an NMA 
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at all, or to present the results from the appropriate inconsistency model (Lu & Ades model when all 
studies are two-armed; design-by-treatment model when multi-arm trials are present) along with the 
direct evidence and a warning to the readers of the limitations of the analysis.  
TABLE 1 HERE 
5 Software options for fitting an NMA model and evaluating 
inconsistency 
Our literature search showed that BUGS software is a popular choice for implementing new 
methods in NMA, the majority of the articles included in our database reported using WinBUGS, 
OpenBUGS (Lunn et al., 2009, 2000) or JAGS (Plummer, 2003): (Achana et al., 2013; Ades, 2003; 
Ades et al., 2010; Caldwell et al., 2012, 2010, 2005; Carlin et al., 2013; Chaimani et al., 2013b; 
Chaimani and Salanti, 2012; Cooper et al., 2011, 2009; Cope and Jansen, 2013; Dakin et al., 2011; Del 
Giovane et al., 2013; Dewilde and Hawkins, 2012; Dias et al., 2013a, 2013b, 2013c, 2013d, 2010a, 
2010b, 2010c; Ding and Fu, 2012; Donegan et al., 2013a, 2013b; Efthimiou et al., 2014a, 2014b; 
Franchini et al., 2012; Govan et al., 2010; Griffin et al., 2006; Higgins and Whitehead, 1996; Hoaglin 
et al., 2011; Hong et al., 2013a, 2013b; Jansen, 2011; Jansen et al., 2008; Jansen and Cope, 2012; Jonas 
et al., 2013; Jones et al., 2011; Lu et al., 2007; Lu and Ades, 2009, 2006, 2004; Madan et al., 2014, 
2011; Mavridis et al., 2013; Mills et al., 2013a; Nixon et al., 2007; Ohlssen et al., 2013; O’Regan et al., 
2009; Ouwens et al., 2010; Price et al., 2011a, 2011b; Salanti et al., 2011, 2010, 2009; Saramago et al., 
2012; Schmid et al., 2013; Schmidli et al., 2013; Schmitz et al., 2013, 2012; Soares et al., 2013; Song 
et al., 2012; Spineli et al., 2013; Sturtz and Bender, 2012; Thorlund et al., 2014, 2013; Thorlund and 
Mills, 2012a; Trinquart et al., 2012a, 2012b; Tu and Faggion, 2012; van Valkenhoef et al., 2012a; 
Warren et al., 2014; Wells et al., 2009; Welton et al., 2012, 2010, 2009, 2008; White et al., 2012; 
Woods et al., 2010; Zhang et al., 2013). An alternative option for implementing Bayesian statistical 
inference is Stan, a recently developed programming language (Stan Development Team, 2014). 
However, we did not identify any articles using Stan. 
Also, there were many articles that reported the use of R (R Core Team, 2014): (Chung and Lumley, 
2008; Dias et al., 2010b; Donegan et al., 2013a, 2012; Jansen, 2012; Krahn et al., 2013; Lu et al., 2011; 
Lu and Ades, 2009; Lumley, 2002; Mills et al., 2013a, 2011b; Naudet et al., 2013; Rücker, 2012; 
Rücker and Schwarzer, 2014; Salanti et al., 2009; Schmid et al., 2013; Song et al., 2012; Sturtz and 
Bender, 2012; Tan et al., 2014; Thorlund et al., 2014; Thorlund and Mills, 2012a; Trinquart et al., 
2012b; van Valkenhoef et al., 2012a, 2012c; Veroniki et al., 2013; Zhang et al., 2013); some papers 
used STATA (StataCorp., 2013): (Ballesteros, 2005; Chaimani et al., 2013a; Franchini et al., 2012; 
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Higgins et al., 2012; Jonas et al., 2013; Madan et al., 2011; Norton et al., 2012; Tu and Faggion, 2012; 
Veroniki et al., 2013; Warren et al., 2014; White et al., 2012) and a few papers reported using SAS 
software (SAS Institute, 2011): (Carlin et al., 2013; Hong et al., 2013b; Jonas et al., 2013; Jones et al., 
2011; Piepho et al., 2012; Piepho, 2014; Piepho et al., 2015; Signorovitch et al., 2012). Finally, Van 
Valkenhoef et al. (van Valkenhoef et al., 2012a) presented GeMTC, a freely-available, open-source 
program for performing NMA.  
Neupane et al. performed a review of the available automated packages for performing an NMA in 
R aiming to summarize the key features and functionality of each package (Neupane et al., 2014). In 
Table 2 we describe possible software solutions for some of the models presented in this review.  
TABLE 2 HERE 
6 Other issues in NMA 
6.1 The use of different measures of effect size 
There is a wide choice of summary effect measures that can be used for the meta-analysis of 
evidence on a binary outcome. The most common choices are the odds ratio (OR), risk ratio for 
harmful or beneficial outcomes (RRH and RRB), risk difference (RD) and hazard ratio (HR) for time-to 
event data. Donegan et al. (Donegan et al., 2010) reported that the majority of the published NMAs of 
dichotomous data used OR and RR (50% and 40% respectively), with RD being used in only 10% of 
the analyses. Veroniki et al. (Veroniki et al., 2013) analyzed 40 published networks and showed that 
the choice of effect measure may have an impact on the inferences about the statistical inconsistency. 
This was also discussed by Coory and Jordan (Coory and Jordan, 2010); using information from 
published networks they concluded that the use of OR and RR is preferable over RD. In addition, it has 
been demonstrated that the choice of the scale may have an impact on the results of an NMA (Gleser 
and Olkin, 2009). In particular, Eckermann et al. (Eckermann et al., 2009) showed that the use of RR 
may lead to inferential fallacies and advocate the use of OR. Norton et al. (Norton et al., 2012) 
discussed that different choices of scale may lead to differences in the ranking of the treatments in an 
NMA. They propose that researchers should explore how sensitive the NMA results are in the choice of 
effect measure. Van Valkenhoef and Ades (van Valkenhoef and Ades, 2013) on the other hand discuss 
that a rank reversal is unlikely to take place unless the assumptions underlying NMA do not hold or the 
data is very sparse; thus, if a rank reversal is observed when using a certain effect measure then the 
transitivity assumption  is unlikely to hold irrespectively of the choice of effect measure. 
In principle, the choice of the summary statistic in any meta-analysis should be dictated (if possible) 
by biological justifications regarding the disease (Walter, 2000) and also by empirical evidence (Deeks, 
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2002). Alternatively, it is possible to fit models using alternative effect measures and make a choice by 
comparing model fit. Caldwell et al. proposed the use of the posterior mean deviance and the deviance 
information criterion (DIC) to evaluate the model fit of the different effect measures in an NMA 
(Caldwell et al., 2012). The choice of the effect measure can also be guided by comparing the estimates 
of between-study heterogeneity, with lower values being preferable. This, however, may be impractical 
when there are few data available, in which case the choice of scale may be driven by the ease of 
interpretation and understanding of the disease process (Caldwell et al., 2012; Dias et al., 2013a). 
Analysts should also keep in mind that the choice of the effect measure for modeling may be different 
than the scale used for decision-making (Egger et al., 1997); e.g. OR may be preferred for data analysis, 
while RR or RD are easier to interpret and can be used to better communicate results with patients or 
clinicians (Walter, 2000). 
 Moreover, HR should always be considered as a suitable choice of scale for the case there is an 
underlying time-to-event process and the proportional hazards assumption is deemed plausible 
(Caldwell et al., 2012; Soares et al., 2013) (see Section 6.3 for additional details on the methodology). 
Also note that the discussion of this paragraph pertains to the analysis of a binary outcome. When 
continuous data is available the analysts should avoid dichotomization since it translates into a loss of 
power and also because the choice of cut-off point may impact on the inferences of NMA (Schmitz et 
al., 2012).  
6.2 Modelling time-to-event data 
In many RCTs the outcome measured is the time to the occurrence of an event (e.g. death, disease 
progression etc.). Welton et al. (Welton et al., 2010) described a method for simultaneously 
synthesizing survival and disease progression outcomes in a single NMA analysis; also, Woods et al. 
(Woods et al., 2010) provided guidance on how to perform an NMA on the log-hazard scale when 
studies report different survival statistics.  
Analysts should keep in mind that the synthesis of time-to-event data in terms of hazard ratios relies 
on the proportional hazards assumption. Treatment effects, however, may vary over time and this might 
threaten the validity of the meta-analysis results. For NMA this might have an extra impact on the 
consistency of the results. Ouwens et al. (Ouwens et al., 2010) and Jansen (Jansen, 2011) modeled the 
hazard functions using parametric survival curves and fractional polynomials of time respectively; in 
these models the hazard ratio is allowed to vary over time. Jansen and Cope (Jansen and Cope, 2012) 
discussed methods for extending these models by including study-level covariates (such as study date) 
that can reduce possible inconsistencies and bias. In another paper by the same authors (Cope and 
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Jansen, 2013), various alternative summaries were presented for summarizing the estimates of the 
relative treatment effects obtained from an NMA of survival data. 
6.3 Extension of NMA models to account for effect modifiers 
In a pairwise meta-analysis a meta-regression on important effect modifiers can explain the presence 
of between-study heterogeneity, which may hinder the interpretation of the results and may have 
important implications in decision making (Dias et al., 2013b). In NMA interpreting results will be 
even more problematic in the presence of evidence inconsistency; meta-regression techniques in NMA 
adjust the treatment effects for possible effect-modifiers and can reduce heterogeneity and 
inconsistency in the results that may be present when these covariates are distributed unevenly among 
studies (Achana et al., 2013; Cooper et al., 2009; Dias et al., 2013b; Greco et al., 2013; Hoaglin et al., 
2011; Jonas et al., 2013; Nixon et al., 2007; Salanti et al., 2009). The effect modifiers can be either 
categorical or continuous variables, and may represent either patient-level or trial-level characteristics.  
6.3.1 General model for including effect modifiers in the analysis 
Nixon et al. (Nixon et al., 2007) first combined NMA and meta-regression techniques to develop 
models that allow the simultaneous comparison of multiple competing treatments while adjusting for 
study-level covariates in an attempt to investigate and explain heterogeneity. Salanti et al. (Salanti et al., 
2009) and Cooper et al. (Cooper et al., 2009) proposed the use of meta-regression as a tool for 
eliminating inconsistency as well as heterogeneity in NMA. As an example of adding covariates in 
NMA Salanti et al. (Salanti et al., 2009) considered the year of randomization in each trial as a 
covariate in an NMA for topical fluoride treatments for the prevention of dental carries. The covariate 
adjusted for possible time trends in the placebo-controlled comparisons and relative treatment effects 
were estimated for a pre-defined year of randomization (the year of the most recent study).  
In general, there are three main approaches in the meta-regression of study-level covariates for 
NMA (Cooper et al., 2009; Dias et al., 2013b): using different and unrelated interaction terms 
(coefficients), using exchangeable interaction terms and using a common interaction term.  
Unrelated interaction terms 
In this approach there are a number of interaction terms for each covariate equal to the number of 
the basic parameters of the model. Let us assume for simplicity that we are only interested in one 
study-level covariate 𝑥𝑥𝐷𝐷. We can augment the hierarchical random-effects model previously presented 
as follows: for a study 𝑖𝑖 , comparing treatments B versus C, we allow 𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴~𝑁𝑁(𝜇𝜇𝐴𝐴𝐴𝐴 +
𝑥𝑥𝐷𝐷𝛽𝛽𝐴𝐴𝐴𝐴 , 𝜏𝜏2), assuming a common heterogeneity variance 𝜏𝜏2 for the treatment effects. If treatment A is 
chosen to be the reference treatment, we can utilize the consistency equations to write 𝜃𝜃𝐷𝐷𝐴𝐴𝐴𝐴~𝑁𝑁(𝜇𝜇𝐴𝐴𝐴𝐴 −
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𝜇𝜇𝛢𝛢𝛢𝛢 + 𝑥𝑥𝐷𝐷(𝛽𝛽𝛢𝛢𝛢𝛢 − 𝛽𝛽𝐴𝐴𝐴𝐴), 𝜏𝜏2); in a Bayesian analysis the 𝛽𝛽𝐴𝐴𝑖𝑖  ‘basic’ coefficients (where T≠A) can be 
assigned unrelated vague prior distributions. 
Exchangeable interaction terms 
The model has the same structure as the model for unrelated interaction terms, but now the basic 
coefficients are drawn from a common distribution, 𝛽𝛽𝛢𝛢𝛢𝛢~𝛮𝛮(𝑏𝑏, 𝜏𝜏𝑏𝑏2) where index T runs through all 
treatments except reference treatment A. The mean 𝑏𝑏 and the variance 𝜏𝜏𝑏𝑏2 of the common distributions 
can be assigned vague priors. 
Common interaction term 
The common interaction term model is the same as the exchangeable interaction model described in 
the previous paragraph, but now all basic interaction terms are assumed equal, 𝛽𝛽𝛢𝛢𝛢𝛢 = 𝛽𝛽 , for all 
treatments T≠A. A vague prior is then assigned to 𝛽𝛽. This model implies that the relative treatment 
effects between the non-reference treatments are independent of the covariate, since the interaction 
terms cancel out. In this case the choice of the reference treatment becomes important, as it might 
change the meta-regression results (Dias et al., 2013b). 
6.3.2 NMA meta-regression for baseline risk 
The underlying risk of the disease, usually termed as ‘baseline risk’, is a proxy for important patient 
characteristics that may be possible modifiers of the treatment effects and it can be included as a 
covariate in an NMA; however, care should be taken to account for its correlation with the treatment 
effects (Achana et al., 2013; Dias et al., 2013b). Achana et al. (Achana et al., 2013) proposed a random-
effects meta-regression model in which the effect of the reference treatment was used as a measure of 
the baseline risk. In order to include studies not reporting the reference treatment the authors proposed 
three alternative distributional assumptions for the ‘true’ unobserved baseline risk. Following Cooper et 
al. (Cooper et al., 2009), the interaction terms were taken to be independent, exchangeable or common. 
The authors recommended that the goodness of fit of the various alternative configurations can be 
based on residual deviance. 
6.3.3 Limitations of NMA meta-regression models  
Analysts should keep in mind that network meta-regression inherits all the interpretation difficulties 
of meta-regression for the case of pairwise meta-analysis, most importantly the inability to directly 
infer on causal relationships (Dias et al., 2013b), and the risk of ecological bias if study-level covariates 
are used to infer about individuals. Another drawback of meta-regression models for decision-making 
in general is that in order to assess the magnitude of the relative treatment effects the analyst must 
choose a value of the covariate at which to make the comparison (Hoaglin et al., 2011).  
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Regarding the choice between the three meta-regression models we presented, the unrelated 
interaction terms approach requires a sufficient number of studies to inform each pairwise comparison. 
In the common case where some of the comparisons in the network are performed in only few studies 
(or even worse in only one study) the coefficients cannot be properly estimated. Moreover, Dias et al. 
(Dias et al., 2013b) advocate that even though the use of models with exchangeable coefficients seems 
attractive, they are likely to lead to situations where decision making on the optimal treatment will 
depend on the value of the covariate. In addition, when there are comparisons in the network informed 
by a low number of studies the ranking of the treatments might be based in non-robust results. 
Therefore, even though the exchangeable coefficient model – or even more complex models – can be 
fitted, the authors suggest that their use should be limited to exploratory analyses. For these reasons the 
common interaction approach might be the safest choice for most networks, but analysts should keep in 
mind the rather strong assumption it employs (i.e. all interaction terms are equal) and that it heavily 
depends on the choice of reference treatment. 
6.4 Investigating potential sources of bias in NMA 
When combining results from different studies in a (pairwise or network) meta-analysis researchers 
always run the risk of obtaining biased estimates of the relative treatment effects for the target 
population. This may be the case when some of the studies provide a biased estimate of the treatment 
effect for their population of interest (which may or may not be the same as the target population of the 
meta-analysis). For example treatment effects may be overestimated in studies of low methodological 
quality. This relates to the so-called ‘internal validity’ of the included studies. The pooled result of a 
(network) meta-analysis may, however, still be biased even if the included studies have no internal 
biases. This might be the case, for example, when the included studies refer to populations different 
than the one targeted by the meta-analysis or when studies without ‘statistically significant’ results 
have not been published (Turner et al., 2009). This rather relates to the generalizability (sometimes 
referred to as ‘external validity’) of the included studies with respect to the targeted question or 
population.  
Dias et al. (Dias et al., 2013b) discussed that when confronted with studies of mixed quality, 
researchers have three options: they can choose to analyze only the high-quality studies, thus ignoring a 
possibly important amount of information, they can choose to analyze all evidence, thus risking a bias 
in the pooled estimates, or they can include all studies after taking into account and adjusting for 
possible biases in the studies. In what follows we focus on the latter, presenting various available 
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approaches for adjusting for suspected internal biases in the included studies, and also for adjusting for 
various forms of external bias.  
6.4.1 Accounting for study limitations in NMA 
Several approaches can be used to account for the potential presence of biases in meta-analysis. 
Spiegelhalter and Best proposed an additive bias model to adjust for both external and internal biases 
(Spiegelhalter and Best, 2003). More advanced methods account for multiple sources of bias, where the 
contribution of each source is modeled separately; see for example (Eddy and Shachter, 1992; 
Greenland, 2005, 2003; Wolpert and Mengersen, 2004). A straightforward but more resource-intensive 
approach to adjust for bias is by eliciting bias distributions (Turner et al., 2009). This involves 
assigning a number of independent experts to evaluate each study in terms of some predefined criteria 
that may indicate the presence of bias. This information can be used to construct an overall bias 
distribution. The parameters of this distribution are combined with the estimates of the studies in order 
to produce a bias-adjusted estimate of the treatment effect in each study. These estimates can then be 
synthesized using standard NMA techniques. 
Models that account for bias usually assume that biased studies yield inaccurate treatment effects of 
size 𝜇𝜇 + 𝛽𝛽, where 𝜇𝜇 is the unbiased treatment effect and 𝛽𝛽 is a bias parameter. For the case of network 
meta-analysis, if the study-specific bias parameters are assumed to be exchangeable across studies the 
unbiased treatment effects and the mean bias can be estimated from the network (Dias et al., 2013b, 
2010c). Dias et al. (Dias et al., 2010c) presented a model where exchangeable bias parameter with non-
zero mean were included in studies that compared an active versus an inactive treatment and were 
considered to be of a high risk of bias (according to some predefined measure such as allocation 
concealment, blinding or other trial characteristics). They also explored the use of two different bias 
parameters, one for active versus inactive, and one for active versus active comparisons; note that in 
this approach some assumption on the direction of bias in the active versus active trials is necessary to 
be made. Salanti et al. (Salanti et al., 2010) considered a similar model in which the newest treatments 
were favored, thus adjusting the treatment effects for possible ‘optimism’ or ‘novelty’ bias (Dias et al., 
2010a). Study size can be a proxy for the study’s risk of bias and Chaimani and Salanti (Chaimani and 
Salanti, 2012) presented a method for adjusting for the ‘small study effects’, the exaggeration of 
treatment effects in smaller trials. This exaggeration might be due to methodological differences 
between smaller and larger trials that affect treatment effectiveness, due to publication bias or due to 
reporting bias. They proposed a network meta-regression model, where the bias parameter is multiplied 
with the observed variance of the treatment effects in each study; the standard error or the precision 
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(inverse variance) can be used alternatively. Their model can also adjust for suspected ‘sponsorship’ 
bias, for the case when interventions are sponsored in some of the studies.  A similar model was also 
presented by Trinquart et al. (Trinquart et al., 2012b). 
6.4.2 Selection model to account for publication bias 
Mavridis et al. (Mavridis et al., 2013) proposed a Bayesian implementation of the Copas selection 
model (Copas, 1999) for addressing for possible publication bias in NMA. The idea behind selection 
models is that the observed set of published studies is considered to be a ‘biased’ sample, due to the 
nature of the publication process. This is addressed by introducing a latent variable for each study, the 
‘propensity of publication’, which is assumed to be correlated with the study’s effect size. Mavridis et 
al. (Mavridis et al., 2013) modeled propensity via a regression model, where it was assumed to be 
inversely proportional to the standard error of the effect size. They considered alternative scenarios of 
how the selection model parameters depend on the treatments being compared in each study. Trinquart 
et al. also presented a selection model (Trinquart et al., 2012b) which modeled the propensity score of a 
trial as a linear function of the standard error. The effect sizes of the studies were weighted according 
to their propensity. Their model was shown to yield similar results to the model by Mavridis et al. 
(Mavridis et al., 2013). 
6.4.3 Accounting for ecological bias 
The meta-analysis of aggregated data can lead to ecological bias. This refers to a bias that may arise 
when using aggregated data in order to make inferences about patient-level interactions. Govan et al. 
(Govan et al., 2010) proposed an NMA model to control for ecological bias by specifically modeling 
the effects of the covariates. Their model allows the inclusion of studies that provide information on all 
covariates, studies that report marginal data on some of the covariates and also studies not providing 
any covariate information at all. The model allows the joint estimation of both the treatment and the 
covariate effects. 
6.4.4 Graphical approaches to bias 
In a different approach Salanti et al. (Salanti et al., 2008b) discussed how the geometry of the 
network can offer insight on the presence of a ‘comparator preference’ bias, i.e. when head-to-head 
comparisons between effective treatments are deliberately avoided, which in turn would imply that the 
treatment effects versus the reference treatments might be exaggerated. The authors utilized two indices 
from ecological literature: diversity, which is a measure of the number of treatments present in the 
network and how often they were tested, and co-occurrence, which measures whether specific 
treatment comparisons were preferred in the network while others were avoided. Limited diversity and 
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significant co-occurrence in a network is an indicator of possible preference bias in the network 
(Ioannidis, 2009). 
Jansen et al. (Jansen et al., 2012) discussed the use of directed acyclic graphs (DAGs) as a graphical 
tool for conceptually evaluating the consistency assumption and also identifying possible sources of 
bias in indirect and mixed treatment estimates. By means of DAGs they showed that NMA estimates 
can be biased when relative treatment effect modifiers vary across comparisons and are not adjusted for 
in the analysis. They also showed that adjusting for covariates that are not effect modifiers is not only 
unnecessary, but that it can introduce bias. 
6.4.5 Empirical assessments of the impact of bias in NMA 
Chaimani et al. (Chaimani et al., 2013b) performed a network meta-epidemiological study to 
explore the effect of trial characteristics and study precision in NMA. They analyzed 32 networks and 
found evidence that imprecise studies (studies reporting broader confidence intervals for their estimates) 
tend to report larger effects compared to more precise studies, thus altering the results of the NMA. 
However, they found no evidence of association between effect size and previously identified 
indicators of bias, including blinding, allocation concealment and random sequence generation. 
Trinquart et al. (Trinquart et al., 2012a) used data from 74 FDA-registered placebo-controlled studies 
on 12 antidepressants along with 51 corresponding publications in order to assess the impact of 
publication bias. They found that the effect sizes derived from published studies differed from the ones 
derived from the FDA data by at least 100% for almost half of the pairwise comparisons. They 
concluded that reporting bias alters NMA estimates and changes the treatments’ ranking. They also 
noted that the impact of reporting bias may be more important in NMA compared to classical meta-
analyses, in the sense that reporting bias in one treatment comparison may have an effect in the ranking 
of all treatments in NMA.  
6.5 Reporting results from NMA 
Although the implementation of NMA is increasingly gaining popularity, the quality of reporting 
has been rather low. Various meta-epidemiological studies of published NMAs showed that the 
methods used and the assumptions made were not routinely reported (Bafeta et al., 2013; Donegan et 
al., 2010; Lee, 2013; Nikolakopoulou et al., 2014). Ohlssen et al. (Ohlssen et al., 2013) presented a 
checklist of items that should be reported in a drug-safety Bayesian NMA while Ades et al. (Ades et 
al., 2013) and Mills et al. (Mills et al., 2012a) give guidelines for those reviewing an NMA for the 
purposes of decision making. 
One possible hurdle in the reporting of an NMA is that presenting all results can be a challenging 
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task, especially for networks with many treatments and multiple outcomes. The literature offers a 
plethora of graphical and tabular methods for visualizing the evidence base (Chaimani et al., 2013a; 
Chung and Lumley, 2008; Senn et al., 2013), the assumptions made (Chaimani et al., 2013a; Krahn et 
al., 2013) and the results obtained from an NMA (Chaimani et al., 2013a; Chung and Lumley, 2008; 
Fadda et al., 2011; König et al., 2013; Salanti et al., 2011; Senn et al., 2013; Tan et al., 2014). In a 
meta-epidemiological study on the presentational approaches used, Tan et al. (Tan et al., 2013) 
examined NMAs published in the UK and found that there is no standardized presentational approach 
for reporting the results of NMA. The authors concluded that a standardization of reporting is required. 
6.6 Modelling multiple outcomes and repeated measures  
RCTs commonly report on more than one outcome. These outcomes may be correlated within a 
study (due to the fact that observations come from the same set of patients) and in addition the true 
treatment effects on the outcomes can be correlated across studies (reflecting the way outcomes are 
related when measured in different settings). The usual meta-analytical approach on multiple outcomes 
is to analyze each one separately, ignoring all possible correlations. On the other hand, a joint meta-
analysis of all outcomes which incorporates possible correlations can increase precision by ‘borrowing 
of strength’ across outcomes and may reduce the impact of outcome reporting bias (Jackson et al., 2011; 
Kirkham et al., 2012).  
Welton et al. (Welton et al., 2008) described a method for performing an NMA of two correlated 
outcomes for the case when all studies are two-armed. Hong et al. (Hong et al., 2013a) presented a 
model for multiple outcomes that does not take into account within-study correlations. Schmid et al. 
(Schmid et al., 2013) proposed a model for unordered categorical data that also allows the inclusion of 
studies with partially observed data. Efthimiou et al. (Efthimiou et al., 2014a) developed a method for 
multiple binary outcomes, where information on the correlations is elicited from expert clinicians. Also, 
Efthimiou et al. (Efthimiou et al., 2014b) presented two models that can be used to perform a joint 
NMA for correlated dichotomous, continuous, time-to-event or mixed outcomes: the first of these 
models can be used when within-study correlations are available, the second when these correlations 
are unavailable. 
Competing risks is a special case of multiple-outcome structure where the outcomes are mutually 
exclusive; Ades et al. (Ades et al., 2010) presented methods for performing a competing-risks NMA. 
Price et al. (Price et al., 2011a) discussed methods for an NMA in multi-state Markov models; a model 
averaging technique was also proposed (Price et al., 2011b) for combining estimates from alternative 
multi-state models.  
Published in final edited form as: Res Synth Methods. 2016 Sep;7(3):236-63. doi: 10.1002/jrsm.1195 
29 
 
In some cases, studies may report on a single outcome for multiple time points, which leads to a 
series of correlated observations. Lu et al. (Lu et al., 2007) proposed a hierarchical NMA model for 
synthesizing repeated measures of a discrete outcome. Dakin et al. (Dakin et al., 2011) suggested a 
model that can handle a continuous outcome, but did not include in the analysis the correlations 
between the observations. Ding and Fu (Ding and Fu, 2012) also presented a model for a continuous 
outcome that automatically modeled the correlations between the observations at different time points. 
Madan et al. (Madan et al., 2014) presented methods for analyzing two dichotomous outcomes reported 
on multiple time points, for studies comparing complex interventions.  
Using NMA results to decide which of all available treatments is optimal for a specific condition 
might be a non-trivial issue, when the treatments are compared for more than one outcome. In order to 
facilitate decision making in the presence of multiple outcomes, Van Valkenhoef et al. (van Valkenhoef 
et al., 2012c) proposed a method for multiple criteria benefit-risk assessment of all competing 
treatments in an NMA; also, Hong et al. (Hong et al., 2013b) described a similar method for producing 
an overall ranking of the treatments in the network using a scoring system for combining efficacy and 
safety outcomes.   
6.7 Definition of nodes in the treatment network 
One important decision that analysts must make at the onset of an NMA regards the number of 
nodes (treatments) to be included in the network, with a simple choice being to include all relevant 
treatments. As discussed in Section 3.1.1 the parameters of interest in an NMA are the relative 
treatment effects between the various competing treatments for a target disorder and a target 
population; however, a decision-maker may not be interested in all pairwise comparisons. The relative 
treatment effect between two active treatments might be more important to decision making than the 
relative effects of active treatments versus placebo. When this is the case, researchers may simplify the 
network by focusing on just a subset of the available treatments, i.e. the ones that are deemed to be 
clinically relevant (e.g. newer/more effective treatments). This, however, poses a dilemma: including in 
the evidence base studies that compare treatments that are not clinically interesting may provide 
additional indirect evidence for the clinically interesting ones, which in turn may increase the precision 
of the estimates (Li et al., 2011; Salanti, 2012); on the other hand, obtaining all relevant evidence in 
order to include clinically uninteresting treatments in the network may be very time consuming and it 
may also lead to additional inconsistencies (Sturtz and Bender, 2012). 
Hawkins et al. (Hawkins et al., 2009b) performed an empirical study that supported the use of all 
potentially relevant data; in another empirical study Mills et al. (Mills et al., 2013a) concluded that the 
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exclusion of treatments in an NMA might have an important effect on the results and might limit its 
usefulness, if important comparisons are excluded. To address this issue Hawkins et al. (Hawkins et al., 
2009a) presented two alternative iterative search strategies for identifying an efficient set of evidence, 
where the comparators included in each search is determined by the results of the previous iteration. In 
addition, Cooper et al. (Cooper et al., 2011) showed that extending the network to include more 
treatments might lead to increased heterogeneity, which in turn will increase the uncertainty in the 
results despite the inclusion of additional information.  
Another challenging issue of NMA relates to the definition of nodes in the network. It is not 
uncommon for treatments – although defined similarly – to be administered in different ways across the 
trials; for instance trials that involve the same drug may apply different doses. Alternatively, it might be 
the case that some of the drugs belong to the same drug class. In such scenarios it is unclear whether 
and how similar treatments should be grouped into nodes. Also, as the included studies adopt 
increasingly different definitions of the nodes transitivity becomes a less plausible assumption. This, in 
turn may lead to increased inconsistency and/or heterogeneity in the results (Dewilde and Hawkins, 
2012; Salanti, 2012). Decisions about whether or not to group similar treatments in a node should be 
therefore guided by clinical considerations regarding their similarity and the research question at hand. 
In addition, Del Giovane et al. (Del Giovane et al., 2013) and also Warren et al. (Warren et al., 2014) 
discussed several alternative approaches to account for variability in treatment definition. The choice of 
the network structure can then be guided by statistical considerations, after comparing goodness-of-fit 
measures between alternative plausible models. 
In another frequently encountered scenario in which the definition of nodes can be of importance is 
when interventions are administered as a combination of more than one treatment; the simplest 
approach would be to analyze each combination as a different node in the NMA. Welton et al. (Welton 
et al., 2009) and Mills et al. (Mills et al., 2012b) proposed possible scenarios for modeling how 
interventions interact with each other when combined into a complex intervention, with one of the 
approaches being the assumption of additive treatment effects. Thorlund et al. (Thorlund and Mills, 
2012a) performed a simulation study which showed that when the treatment effects are truly additive, 
the conventional NMA model performs poorly in comparison to the additive effects model.  
In summary, even though there is no exact recipe available for setting up the network and defining 
the nodes, the choice should be guided by considerations on the transitivity assumption, the presence of 
statistical inconsistency, the possibility of bias and also practical constraints on the resources available 
for setting up the database. Ideally, whenever possible, decisions about the network structure should be 
described a priori in the protocol in order to avoid selective use of data (Salanti, 2012). 
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6.8 Incorporating Individual Patient Data (IPD) in NMA 
The NMA models we have discussed so far can be used only for the analysis of aggregated data 
(AD) while the meta-regression approaches presented in Section 6.3.1 allow the exploration of the 
effects of only study-level covariates to the relative treatment effects. On the other hand the use of IPD 
in an NMA (either exclusively or in combination with AD) is expected to increase precision and also 
allows the distinction between within-study from across-study associations to be made, so as to avoid 
possible ecological bias (Jansen, 2012). We extensively discuss the statistical methodology and the 
potential advantages of an IPD-MA when pooling head-to-head trials in a companion paper (Debray et 
al., 2015). These advantages also apply to NMA, and access to IPD is particularly relevant when the 
number of included studies is small and the validity of using meta-regression of study-level covariates 
becomes increasingly questionable. The use of patient-level covariates will allow a better evaluation of 
the heterogeneity and inconsistency in the network  (Greco et al., 2013; Hoaglin et al., 2011; Jansen et 
al., 2011b, 2008).  
A few models for including IPD in an NMA have been recently proposed. Saramago et al. 
(Saramago et al., 2012) developed a series of NMA models set in a Bayesian background that can be 
used for the simultaneous synthesis of IPD and AD while incorporating both study and individual-level 
covariates. Their models also allow the inclusion of studies with different designs (cluster and 
individual allocation). The authors found that the incorporation of IPD in the network resulted in an 
increase in the precision compared to an AD-only analysis, even when IPD are available only for a 
fraction of the studies. Donegan et al. (Donegan et al., 2013a, 2012) presented  a model for combining 
IPD and AD in a single analysis with three alternative specifications (unrelated, exchangeable and 
common interactions; see also Section 6.3.1). The inclusion of both IPD and AD in the analysis was 
shown to lead to an increased precision of the estimates of the regression coefficients and a better 
assessment of the consistency assumption. A similar model was proposed by Jansen (Jansen, 2012). In 
the same paper a second, alternative model was also suggested for the case of a binary covariate. The 
author performed a simulation study indicating that the second model is less affected by bias at the cost 
of larger uncertainty in the results. Finally Ali et al. (Ali et al., 2013) discussed the use of IPD in order 
to identify possible interactions between treatment effects and potential effect modifiers; when such 
modifiers are found to be unevenly distributed among studies, the authors suggest that NMA models 
need to account for these differences. 
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6.9 Utilizing data from non-randomized and observational studies  
Ades and Sutton (Ades and Sutton, 2006) discuss that results obtained from RCTs may not be 
necessarily generalizable to a wide population and that randomized studies’ results could be combined 
with information from observational studies or patient registries, after adjusting for potential biases. 
Randomized and non-randomized evidence can be regarded as being complimentary, in the sense that 
observational studies can be considered to be reliable sources of information regarding the population 
baseline, while RCTs regarding intervention effects data. Dias et al. (Dias et al., 2013c) describe how 
non-randomized studies can be used to inform a ‘baseline natural history model’. Evidence from such 
studies can be used to estimate the absolute effect for a reference treatment. This can in turn be 
combined with NMA results for the relative effects of active treatments, in order to obtain an estimate 
of the absolute treatment effects.  
Schmitz et al. (Schmitz et al., 2013) proposed three alternative models for jointly synthesizing 
information from RCTs as well as non-randomized studies: the simplest approach presented was be to 
perform a naïve pooling, disregarding differences in study design; the second  approach was to utilize 
non-randomized studies as prior information, while adjusting for bias due to study design; the third was 
a three-level hierarchical model which accounts for bias and for heterogeneity between trial designs. 
The first of the models (naïve pooling) should only be used as the first step of the analysis, since it 
disregards potential biases in non-randomized trials. The second model (using observational evidence 
as prior information) allows adjusting for biases, but between-trial design heterogeneity is not taken 
into account, and it is not possible to include more than two different trial designs. The third model 
(three-level hierarchical model) addresses these issues and should be preferred. 
Finally, Soares et al. (Soares et al., 2013) discussed the use of observational data for the case that 
there are sparse and few data in an NMA. In their approach such data were used to inform the baseline 
effects, but did not directly contribute to the relative treatment effects.   
6.10 Planning future studies 
The issue of planning future studies based on the results of an existing NMA has received little 
attention in the literature. Thorlund and Mills (Thorlund and Mills, 2012b) and also Snapinn and Jiang 
(Snapinn and Jiang, 2011) provided sample size considerations for determining the statistical power of 
indirect evidence and Mills et al. (Mills et al., 2011b) performed a simulation study to estimate the 
power of indirect comparisons; however,  there is currently little guidance on the design (i.e. treatments 
to be compared) and the sample size needed for updating an existing NMA in an optimal manner. 
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Naci and O’ Conor (Naci and O’Connor, 2013) alternatively suggest the design and conduct of 
prospective NMAs; this would go against the current practice of retrospective NMA, where each 
individual study is planned in isolation from others. They also suggest that the regulatory agencies 
should have an active role in the design of future trials, especially in the selection of comparators and 
in ensuring that the patient populations are comparable in terms of treatment effect modifiers.  
7 Concluding remarks 
In this article we have presented the currently available methodology on NMA. We have described 
major developments in the field, discussed all known relevant issues, highlighted key assumptions 
while providing guidance for the interested researchers.  
Our review has several limitations. Pragmatic decisions needed to be made given the lack of a 
widely accepted terminology referring to network meta-analysis, the abundance of recently published 
articles and the complexity of new methods in order to ensure a timely publication of this review. Thus, 
there may have been articles that presented methodological advances for NMA which we failed to 
identify by not including in our search more online databases and by not hand-searching additional 
journals. We believe, however, that even if the identified set of articles might not be complete, it is 
representative of the currently available methods for NMA and that the most important methodological 
aspects, challenges and solutions of NMA are covered. Moreover, although we present some of the 
mathematical features of the various models and methods, we do it in a descriptive manner and we do 
not provide all relevant details. Hence, this review serves as a roadmap for researchers: the keen reader 
should refer to the original articles for details, keeping also in mind that NMA is still an active, rapidly 
developing research field. 
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Figure 1: Each circle represents an intervention, lines represent direct comparisons. Left panel: Three 
interventions A, B, and C form a simple network. The indirect AB comparison is estimated via C, i.e. 
using the direct AC and BC comparisons. The mixed relative treatment effect for AB is estimated by 
combining the direct comparison and the indirect comparison. Right panel: A more complex network 
with five interventions and eight direct comparisons. Overall, one direct comparison and four indirect 
comparisons contribute evidence to A versus B (indirect comparisons are: via C; via E; via C and D; 
via E and D). 
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Table 1: An overview of the methods for assessing statistical inconsistency along with the limitations of 
each method 
Approach to inconsistency Method Limitations 
Local methods 
Loop-specific 
• Does not compare direct to 
all indirect evidence for each 
comparison 
• Different loops sharing a 
comparison are not 
independent  
• Multiple-testing issues 
Composite test 
Fails to account for 
correlations induce by multi-
arm studies 
Back-calculation 
• Problematic for a random-
effects meta-analysis 
• Cannot properly handle 
multi-arm studies 
Node splitting 
• Computationally intensive 
• Cannot properly handle 
multi-arm studies 
Global methods 
Lu and Ades model 
Depends on parameterization 
when multi-arm studies are 
included  
Design-by-treatment model Non-intuitive definition of 
inconsistency.  
Unrelated mean effects model 
Depends on parameterization 
when multi-arm studies are 
included 
𝑄𝑄 statistic for inconsistency 
Based on the notion of 
design-by-treatment 
inconsistency model (non-
intuitive definition of 
inconsistency) 
Multidimensional scaling Cannot properly handle 
multi-arm studies 
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Table 2: Available software solutions for NMA 
 
Method Software 
Bucher method 
• Stata (indirect command) 
• ITC (Microsoft Windows application, available at  
https://www.cadth.ca/resources/itc-user-guide/introduction) 
NMA as meta-
regression 
• Stata (metareg command: when only two-armed trials are included in the 
network; mvmeta and network commands: in the presence of multi-
armed studies in the network; lincom command can be used to estimate the 
functional parameters in both cases.) 
• R (rma command from  metafor package: when only two-armed studies 
are included) (Viechtbauer, 2010) 
Hierarchical 
NMA model 
• BUGS codes available at: http://www.mtm.uoi.gr and  
http://www.bris.ac.uk/social-community-medicine/projects/mpes/ 
• R (gemtc package (van Valkenhoef and Kuiper, 2015), information available 
at https://drugis.org/software/r-packages/gemtc; pcnetmeta package (Lin et 
al., 2015) available at  http://cran.r-
project.org/web/packages/pcnetmeta/index.html)  
NMA as a 
multivariate 
meta-analysis 
• Stata (mvmeta; network) 
• R (mvmeta) (Gasparrini et al., 2012)  
Graph-theoretical 
approach to 
NMA 
• R (netmeta package: accounts for multi-armed studies available at  
http://cran.r-project.org/web/packages/netmeta/index.html) (Rücker et al., 
2015) 
Loop-specific 
approach for 
inconsistency 
• R (routines available at http://mtm.uoi.gr/index.php/how-to-do-an-mtm) 
• Stata (network graphs, available at  http://mtm.uoi.gr/index.php/stata-
routines-for-network-meta-analysis) 
Node splitting 
approach 
• BUGS (codes available at http://www.bristol.ac.uk/cobm/research/mpes) 
• GeMTC software 
• Stata (network package) 
Lu & Ades model 
• BUGS (codes available at http://www.bristol.ac.uk/social-community-
medicine/projects/mpes) 
• Stata (mvmeta) (Gasparrini et al., 2012) 
• GeMTC software 
Design-by-
treatment model • Stata (mvmeta; network) 
Q-statistics in 
NMA 
• R (netmeta)  
• Stata (mvmeta; network) 
Graphical 
presentation 
• Stata (network graphs, available at http://mtm.uoi.gr/index.php/stata-
routines-for-network-meta-analysis) 
• R (netmeta)  
